<DOC>
	<DOCNO>NCT01022424</DOCNO>
	<brief_summary>ADPKD patient enrol Study 156-05-002 receive repeat oral administration OPC-41061 dose 15 mg twice daily ( morning evening ) . Administration continue time manufacture distribution approval OPC-41061 ADPKD Japan .</brief_summary>
	<brief_title>A Long-term Administration Study OPC-41061 Patients With Autosomal Dominant Polycystic Kidney Disease ( ADPKD ) ( 2 ) Extension Study 156-05-002</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients complete 3year repeated administration followup observation withdrawn study due reason occurrence adverse event ( base judgment either subject investigator/subinvestigator ) preceding study ( 15605002 ) Patients adverse event occur study 15605002 resolve become stable require followup . Patients eGFR less 15 mL/min/1.73 m2 Patients follow complication : Uncontrolled hypertension Serious cardiovascular disease ( eg . heart failure ) hepatic disease ( eg . cirrhosis ) Patients follow complication history thereof : Clinically significant drug allergy ( anaphylaxis ) hypersensitivity ( especially , hypersensitivity benzazepine derivative suspect hypersensitivity Inability personally give consent due mental illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>OPC-41061</keyword>
</DOC>